Explore

Trendline Trendline
Novo Nordisk's IL-6 Inhibitor Ziltivekimab Fails in Cardiovascular Phase 3 Trial, Shares Drop

Novo Nordisk's IL-6 Inhibitor Ziltivekimab Fails in Cardiovascular Phase 3 Trial, Shares Drop

Novo Nordisk's IL-6 Inhibitor Ziltivekimab Fails in Cardiovascular Phase 3 Trial, Shares Drop
Trendline Trendline
Novo Nordisk's Ziltivekimab Heart Drug Fails in Phase 3 Trial, Impacting Stock

Novo Nordisk's Ziltivekimab Heart Drug Fails in Phase 3 Trial, Impacting Stock

Novo Nordisk's Ziltivekimab Heart Drug Fails in Phase 3 Trial, Impacting Stock
Trendline Trendline
Novo Nordisk's ZEUS Trial Fails to Show Cardiovascular Benefits

Novo Nordisk's ZEUS Trial Fails to Show Cardiovascular Benefits

Novo Nordisk's ZEUS Trial Fails to Show Cardiovascular Benefits
Trendline Trendline
Pfizer and Eli Lilly: Divergent Investment Strategies in the Pharmaceutical Sector

Pfizer and Eli Lilly: Divergent Investment Strategies in the Pharmaceutical Sector

Pfizer and Eli Lilly: Divergent Investment Strategies in the Pharmaceutical Sector
Reuters Reuters
AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates

AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates

By Siddhi Mahatole and Puyaan Singh July 31 (Reuters) - AbbVie slightly trimmed its 2026 profit forecast on Friday to account for its planned Apogee Therapeutics acquisition, while topping second-quarter estimates on strong immunology drug sales.
Trendline Trendline
Bicycle Therapeutics Reports Progress and Financial Results for Q2 2026

Bicycle Therapeutics Reports Progress and Financial Results for Q2 2026

Bicycle Therapeutics Reports Progress and Financial Results for Q2 2026
Trendline Trendline
Regeneron Faces Questions Over M Strategy Amid $18 Billion Cash Reserve

Regeneron Faces Questions Over M Strategy Amid $18 Billion Cash Reserve

Regeneron Faces Questions Over M Strategy Amid $18 Billion Cash Reserve
Reuters Reuters
AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

July 31 (Reuters) - AbbVie trimmed its 2026 profit forecast on Friday to account for its planned Apogee Therapeutics acquisition, while topping second-quarter estimates on strong immunology drug sales. Shares of the drugmaker fell more than 4% in premarket trading.
Reuters Reuters
Biogen beats quarterly estimates as newer drugs fuel growth

Biogen beats quarterly estimates as newer drugs fuel growth

July 29 (Reuters) - Biogen reported second-quarter profit and revenue that topped Wall Street estimates on Wednesday, driven by strong demand for its rare-disease medicines, while sales of its legacy multiple sclerosis drugs stayed under pressure.
Trendline Trendline
Amgen's Monthly Weight Loss Drug MariTide Challenges Eli Lilly and Novo Nordisk

Amgen's Monthly Weight Loss Drug MariTide Challenges Eli Lilly and Novo Nordisk

Amgen's Monthly Weight Loss Drug MariTide Challenges Eli Lilly and Novo Nordisk
Trendline Trendline
Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options
Trendline Trendline
Alkermes Reports Break-Even Q2 Earnings, Revenue Surpasses Estimates

Alkermes Reports Break-Even Q2 Earnings, Revenue Surpasses Estimates

Alkermes Reports Break-Even Q2 Earnings, Revenue Surpasses Estimates